Browsing Tag
Regeneron Pharmaceuticals
26 posts
FibroGen and Regeneron Pharmaceuticals forge clinical trial collaboration for cancer treatment
FibroGen, Inc. (NASDAQ: FGEN) has entered into a clinical trial supply agreement with Regeneron Pharmaceuticals, aiming to evaluate…
June 4, 2024
Breakthrough in colorectal cancer as Regeneron Pharmaceuticals reveals promising results from immunotherapy trial
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced encouraging early outcomes from its Phase 1/2 clinical trial, which evaluates…
May 25, 2024
Sanofi, Regeneron get Dupixent EC approval for eosinophilic esophagitis
French pharmaceutical company Sanofi and Regeneron, an American biotechnology company, have received the approval of the European Commission…
February 1, 2023
Regeneron gets Libtayo approval in Japan for advanced cervical cancer
Regeneron Pharmaceuticals has secured the approval of the Japanese Ministry of Health, Labor and Welfare (MHLW) to manufacture…
December 31, 2022
Regeneron says REGEN-COV monoclonal antibodies active against Omicron, Delta and other variants
Regeneron Pharmaceuticals said that the monoclonal antibodies of its REGEN-COV cocktail are active against all known variants of…
December 19, 2021
Roche, Cipla to bring Casirivimab/Imdevimab Covid-19 drug to India
Roche India said that India’s Central Drugs Standards Control Organisation (CDSCO) has granted an emergency use authorisation (EUA)…
May 6, 2021
Regeneron Pharmaceuticals’ Inmazeb FDA approval: A milestone in Ebola treatment
Regeneron Pharmaceuticals has achieved a significant breakthrough with the approval of its antibody cocktail, Inmazeb (atoltivimab, maftivimab, and…
October 15, 2020
Regeneron Pharmaceuticals begins COVID-19 clinical trials of REGN-COV2
US biotech company Regeneron Pharmaceuticals has started the first clinical trial of its investigational dual antibody cocktail REGN-COV2…
June 12, 2020
Dupixent delivers positive results in eosinophilic esophagitis trial
Regeneron Pharmaceuticals and Sanofi said that their co-developed eczema drug Dupixent (dupilumab) has met the co-primary endpoints of…
May 24, 2020
Sanofi, Regeneron secure Libtayo EMA approval for a type of skin cancer
Libtayo EMA approval : The European Commission has given conditional approval for Libtayo (cemiplimab) for the treatment of…
July 21, 2019